ELVN NASDAQ
Enliven Therapeutics, Inc.
1W: -8.9%
1M: -6.2%
3M: +34.6%
YTD: +249.6%
1Y: +182.6%
3Y: +248.7%
5Y: +187.1%
$54.32
-1.91 (-3.40%)
Weekly Expected Move ±4.1%
$50
$52
$54
$57
$59
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$3.9B
52W Range14.785-62.32
Volume995,807
Avg Volume1,225,904
Beta0.24
Dividend—
Analyst Ratings
Company Info
CEORichard A. Fair
Employees67
SectorHealthcare
IndustryBiotechnology
IPO Date2020-03-12
Websiteenliventherapeutics.com
6200 Lookout Road
Boulder, CO 80301
US
Boulder, CO 80301
US
720 647 8519
About Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.
Latest News
Bank of New York Mellon Corp Purchases New Position in Enliven Therapeutics, Inc. $ELVN
Bank of America Corp DE Grows Stock Position in Enliven Therapeutics, Inc. $ELVN
Algert Global LLC Makes New Investment in Enliven Therapeutics, Inc. $ELVN
BlackRock Inc. Invests $221.25 Million in Enliven Therapeutics, Inc. $ELVN
Dimensional Fund Advisors LP Raises Holdings in Enliven Therapeutics, Inc. $ELVN
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Hohl Benjamin | S-Sale | 4,630 | $58.35 | 2026-08-17 |
| Hohl Benjamin | S-Sale | 1,388 | $59.35 | 2026-08-17 |
| Collins Helen Louise | S-Sale | 3,900 | $58.37 | 2026-08-17 |
| Collins Helen Louise | S-Sale | 1,100 | $59.35 | 2026-08-17 |
| Derynck Mika K | M-Exempt | 27,567 | $25.28 | 2026-08-04 |